Accolade, Inc. (NASDAQ:ACCD) Q1 2024 Earnings Conference Call June 29, 2023 4:30 PM ET

Company Participants

Todd Friedman - SVP, IR

Rajeev Singh - CEO

Steve Barnes - CFO

Shantanu Nundy - Chief Health Officer

Conference Call Participants

Ryan Daniels - Blair

Craig Hettenbach - Morgan Stanley

Jeff Garrow - Stephens, Inc.

Jessica Tassan - Piper Sandler

Stephanie Davis - SVB Securities

Ryan MacDonald - Needham and Company

Jonathan Yong - Credit Suisse

Jailendra Singh - Truist Securities

Sandy Draper - Guggenheim

Stan Berenshteyn - Wells Fargo

David Larsen - BTIG

Robert Simmons - D.A. Davidson

Operator

Good day, and thank you for standing by, and welcome to Accolade First Quarter '24 Earnings Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to introduce your host for today's call, Todd Friedman, Senior Vice President of Investor Relations. You may begin.

Todd Friedman

Thanks, operator. Welcome everyone to our fiscal first quarter earnings call. With me on the call today are our Chief Executive Officer, Rajeev Singh; and our Chief Financial Officer, Steve Barnes. Shantanu Nundy, our Chief Health Officer, will join for the question-and-answer portion of the call later.

Before turning the call over to Rajeev, please note that we will be discussing certain non-GAAP financial measures that we believe are important when evaluating Accolade's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and the reconciliations thereof can be found in the press release that is posted on our website.

Also, please note that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause the actual results for Accolade to differ materially from those expressed or implied in this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available on our website.

With that, I'd like to turn the call over to our CEO, Rajeev Singh.

Rajeev Singh

Thank you, Todd, and thank you, everyone, for joining us today.

We entered fiscal Q2 with optimism regarding our company, our category and our opportunity to build a nationwide customer-obsessed healthcare delivery system of the foundation of advocacy-led primary care. Let's get into the reasons for our excitement.